Combinations of antibiotics received by patients with MRSA and MSSA bacteremia at any time during treatment (N = 2741).

1Information on whether combination therapy was used was available for 587 of the 593 patients who were treated, of whom 279 (48%) received combination therapy. Of these, 274 had information on susceptibility to methicillin.272/274 (26%) of patients received more than one type of combination during the same episode.3Information on whether a given combination was used was missing for 2–3 patients for each combination listed.4112 received another 2-drug combination; 13 received 3 or more drugs in combination. Of the 112 who received a 2-drug combination 34 received a glycopeptide + beta-lactam, 12 received a beta-lactam + fluoroquinolone, 12 received a beta-lactam + clindamycin, and 7 received a beta-lactam + macrolide. The remaining 47 received one of 22 different combinations.